

Determinants and outcomes of the choice to switch to dolutegravir within different 3- or 2-drug regimens in a single-center cohort: the DOLUTILITY Study

Restelli S¹, Romeri F², Piscaglia M¹, Rizzelli D², Gallazzi I¹, Paladini L¹, Cossu MV¹, Micheli V² and Capetti AF¹

Main reason for switching therapy, %

3TC n = 47

(b)ATV, n = 59

Toxicity 6.8

Drug – drug

3TC/ABC n = 614

bDRV, n = 95

Adhe 15.1

0XIC 6.5

NRT

bPI 80

70 60



The Dolutility Group

Background Dolutegravir (DTG) was approved for antiretroviral therapy mainly on data from triple association with (b) was supposed for an an economy using pricing starting of data to use it within different two nucleosides, however very soon physicans started to use it within different regimens, including two-drug regimens ^{10,1} in analysis aims to investigate whether various DTG-based regimens have their own specificity and to describe them.

the DOLUTILITY Study is a single-center part of the ODOACRE Cohort. For all the patients who started DTG in any combination from November, 10, 2014, to April, 30, 2017, we collected baseline demographic, pharmacologic, virologic, immunologic and metabolic data, routine clinical data and blood work and outcomes. Only those subjects who had started DTG at least 96 weeks before the analysis (April, 30, 2016) were included. The statistical analysis is based on the Mann-Whitney test and the Wilcoxon test for continuous variables and on the Fisher exact test for contingency.

vere included. The six regimens that were studied are: abacavir/ lamivudine/DTG (ABC/3TC/DTG), n = 614, DTG plus 3TC, n = 47, DTG plus rilpivirine (RPV), n = 132, DTG plus boosted darunavir (bDRV), n = 95, DTG plus boosted/unboosted atazanavir (b/uATV), n = 59, and DTG plus tenofovir/emtricitabine (TFV/FTC), n = 92. Table 1 1039 pati summarizes the baseline demographic and epidemiologic characteristics. Overall, DTG+bDRV and DTG+TFV/FTC had longer time from HIV diagnosis and longer time on herapy (Pc 0,0001 for both), while DTG+bDRV and DTG+RPV had more CDC stage C therapy (P< 0,0001 for both), while DTG+bDRV and DTG+RPV had more CDC stage C diagnosis and history of treatment failure (P< 0,0001 for both), DTG+RPV had often been chosen for concomitant treatment of HCV and HBV coinfection was present only in the DTG+TFV/FTC group. The analysis of past exposure to antiretrovirals and baseline and historical resistance-associated mutations (RAMs) revealed that DTG+bRV and DTG+RPV had the heaviest burden, while DTG+3TC was only slightly affected. Table 2 describes the main reasons for the switch and their statistical relevance, compared to the choice for ABC/3TC/DTG. All the regimens showed >92% efficacy and the few viral failures (12 overall) were not accompanied by the selection of new mutations.

ABC/3TC/DTG being the main choice, DTG/3TC is the choice for subjects with cardiovascular risk, short drug experience and few or no mutations, DTG/RPV for drug-experience subjects who retain sensitivity to both drug and need such regimen to avoid or correct metabolic problems, DTG/bDRV is a regimen for salvage or simplification of salvage, while DTG/b/uATV and DTGTFV/FTC have intermediate profiles.

Introduction

Since the commercial availability of dolutegravir (DTG), perceiving it's antiretroviral Since the commercial availability of doutlegravir (D10), perceiving it's antireformation of the potency, high genetic barrier to resistance and low metabolic impact, several physicians started to use it within and outside the clinical trials' schemes, generating a variety of antirertoviral regimens, fit for the variety of clinical situations and treatment history which characterize the HIV outpatients' population. Camelia Gubavu was the first author to report such heterogeneity ^[3] and we followed with more structured multicentre observational studies, particularly focused on the associations of dolutegravir plus rilpivirine and of dolutegravir plus boosted darunavir as dual regimens in different estimos.

dual regimens in different settings.

With this analysis we mean to investigate how has dolutegravir been used in our center, if indeed different regimens are proposed to different types of subjects, how they are being tolerated and what is the level of efficacy.

Methods

All HIV-1 infected naïve subjects who had taken at least once from Luigi Sacco Hospital Pharmacy dolutegravir (either as TivicayTM or as TriumeqTM) between November 10, 2014 and April 30, 2017 were retrospectively included in an observational cohort. The list of subjects was obtained by the Pharmacy Unit and the relative case record forms were subjects was obtained by the manage price pridemiologic, clinical, pharmacological, investigated gathering demographic, epidemiologic, clinical, pharmacological, immunovirological and metabolic data. For drug resistance, historical data have been gather to form an 'ever observed' mutation set.


Data have been analysed by treatment cohorts (regimens) at 96 weeks of follow-up, with

an accepted window of two months. Fisher exact test and Odds ratio [CI95] were calculated for the different features. The population size was determined by the physicians' choices and by the time window.

Population

			ABC + 3 (n. 614		RPV (n. 132)	b/DRV (n. 95)	(b)ATV (n. 59)	TFV + FTC (n. 92)
Sex	м		485 (79%) 34 (72%)	85(64%)	61 (64%)	34 (58%)	73 (79%)
	F		128 (21%)	13 (28%)	47 (36%)	44 (36%)	25 (42%)	19 (21%)
Ethnicity	Caucasian		500 (81%)	42 (89.4%)	121 (91.7%)	80 (84.2%)	47 (79.7%)	82 (89.1%)
	African		35 (5.7%)	3 (6.4%)	9 (6.8%)	4 (4.2%)	5 (8.5%)	2 (2.2%)
	Asian		11 (1.8%)	2 (4.2%)	2 (1.5%)	/	/	1 (1.1%)
	Hispanic		67 (10.9%) /	/	6 (6.3%)	6 (10.1%)	/
	Other		4 (0.6%)	/	/	5 (5.3%)	1 (1.7)	1 (1.1%)
Age			49.7	39±1	47±1	56.5	54.5±2.5	50,3±6,5
	Heterosexual		215 (35%)	19 (40.5%)	46 (34.8%)	37 (38.9%)	22 (37.3%)	20 (21.6%)
Risk factor	Homosexual		264 (43%)	20 (42.5%)	43 (32.7%)	19 (20%)	18 (30.5%)	35 (38.3%)
	Intravenous Drug User		129 (21%)	8 (17%)	41 (31%)	38 (40%)	19 (32.2%)	37 (40.1%)
	Other		6 (1%)	/	2 (1.5%)	1 (1.1%)	/	/
Conclusions		ABC/	TC				зтс	Ver
	Triple	ABC/.	SIC	Lower incidence of neuropychic AEs compared to the liter		Dall	510	resi





Effective also as proactive switch , the only limitation compared to the SWORD study appears to be full sensitivity to the regimen drugs



Comorbidities (OR, IC95)

LSRO LSRO LSRO LSRO


6,623 6,0734 6,0075 6,0075 6,0075


0,01 0,01 1,03 1,03 1,03 6,6175 6,6175 6,6175 6,6105 6,6105

481 181 1310 1311 6,0005 6,0005 6,0005 6,0005 6,0005 6,0005

1,85 26,61 864,70 16,91 2-12 0,41 1,34 1,81 1,61

Comorbidities (%, total ≥ 100)





RPV n = 132

Simplification

TFV/FTC, n = 92


Proactive switch 20.7

Virologic


10,6




Past exposure to antiretrovirals



Past viral failures (compared to ABC/3TC)



Immunologic and virologic outcomes



More complex to find the best population, probably simplification or NRTI-sparing for subjects already taking ATV

Capetti AF, Cossu MV, Paladini L and Rizzardini G. Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection. Exp. Opin. Pharmacother. DOI: 10/1080/14656566.2017.1417984. Epub 2017 Dec 22. Maggiolo F, Gulminetti R, Pagnucco L, Digaetano M, Benatti S, Valenti D, Calegaro A, Ripamonti D, Mussini C. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. BMC Infect Dis. 2017 Mar 16;17(1):215. Gubavu C, Prazuck T, Niang M, Buret J, Mille C, Guinard J, Avetland-Fencel V, Hocqueloux L. Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patie Antimicrob Chernother. 2016 Apr;71(4):1046-50. nts. J